Advertisement
Home Tags Human Papillomavirus (HPV)

Tag: Human Papillomavirus (HPV)

The prevalence of human papillomavirus (HPV) and of high-risk HPV type 16 or 18 is 4.9 and 3.9 percent

HPV Prevalence 4.9 Percent in Tonsil Tissue of Healthy Adults

0
Human papillomavirus colocalizes to the biofilm of the tonsillar crypts
For patients with human papillomavirus+ stage I or II oropharyngeal cancer

Reducing Tx May Harm Safety in Early HPV+ Oropharyngeal Cancer

0
For patients with stage III disease, intensification to triple-modality therapy may improve survival
For patients with human papillomavirus-associated cancers

Sex, Race, Age Disparities in Survival for HPV-Linked Cancer

0
Whites have consistently higher five-year survival than blacks for all cancers across all age groups
The five-year risks of cervical intraepithelial neoplasia grade 3 (CIN3)

Risk of ≥CIN3 Drops With Negative HPV, Cytology Co-Tests

0
Decrease in 5-year ≥CIN3 risks after each successive negative round of HPV, cytology co-testing
The incidence of juvenile-onset recurrent respiratory papillomatosis in Australia decreased from 2012 to 2016 after implementation of a quadrivalent human papillomavirus vaccination program for females aged 12 to 26 years in 2007-2009

HPV Vaccine Tied to Reduced Respiratory Papillomatosis Rate

0
Reduction in incidence of juvenile-onset recurrent respiratory papillomatosis from 2012 to 2016
Men have a higher prevalence of oncogenic oral human papillomavirus than women

Oncogenic Oral HPV DNA Detected in 3.5 Percent of Adults

0
Prevalence of oncogenic oral HPV higher in men, rises with number of lifetime oral sexual partners
Oral human papillomavirus (HPV) infection and high-risk oral HPV infection are more common among men than women

Prevalence of Oral HPV Infection Higher for U.S. Men

0
Overall prevalence 11.5 percent in men, 3.2 percent in women; high-risk HPV also more prevalent in men
For HIV-infected men who have sex with men

HPV Vaccination After Lesion Treatment Is Likely Cost-Effective

0
Adjuvant HPV vaccination could reduce anal cancer risk in HIV-infected men who have sex with men
For patients with human papilloma virus-related oropharynx squamous cell carcinoma

ASTRO: Aggressive Reduction of Radiation Beneficial in OPSCC

0
In HPV-related disease, the approach linked to high cure rates, reduced side effects
The U.S. Preventive Services Task Force (USPSTF) recommends cervical cancer screening with cervical cytology alone every three years or screening with high-risk human papillomavirus testing alone every five years in women ages 30 to 65 years. These findings form the basis of a draft recommendation statement published online Sept. 12 by the USPSTF.

USPSTF Backs Cervical Cancer Screening With Cytology or hrHPV

0
Recommendations for screening with cytology alone every three years or hrHPV testing every five years